Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
When Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.
Ibogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.
Windward Bio’s public debut brings this year’s total IPO count well above the sluggish total of eight in 2025.
Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.
ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persistence on treatment.
In this webinar, we will show how delayed isolation and cryopreservation of immune cells from fresh leukopaks can drastically impact their stability and functionality. We will also explore how purified and cryopreserved cell populations such as PBMCs and isolated T cells streamline logistics, reduce variability, and enhance transduction efficiency in CAR-T production.
BioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.
Addex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for treating schizophrenia with its 2024 approval.
In advance of a Senate vote on Heidi Overton as the next FDA commissioner, the agency has shelved the Commissioner’s National Priority Voucher program introduced by former leader Marty Makary, Reuters reported Thursday.
Follow along as BioSpace tracks job cuts and restructuring initiatives.
PRESS RELEASES
• OST-HER2 remains eligible for Priority Review Voucher (“PRV”) if approved by the U.S. Food and Drug Administration’s (“FDA”) on or before September 30, 2029 • Company continues to benefit from its UK research and development program, through which it received approximately $900,000 in non-dilutive tax credits
Appointment Follows US$6.5 Million Strategic Financing and Strengthens Board Leadership Alongside David Adelman, Kevin Mayer, Lee Applbaum and James McRoberts
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2027
Building a National Security Healthcare company focused on dual-use medical technologies